To comply with the new law, the U.S. Department of Education recently issued a draft rule that would impose limits on how much graduate students can borrow — up to $20,500 per year and $100,000 in ...

In this first-person essay, author and writing coach Emily Rubin shares her shock and resolve regarding a second breast cancer diagnosis after many years in remission.

SLNB, which involves surgical removal and analysis of a lymph node closest to the primary tumor, is the preferred method for axillary staging in early-stage breast cancer. However, accumulating ...

“Personalized, risk-based screening is critical to improving breast cancer outcomes, and AI tools offer us the best opportunity to fulfill that potential,” said Robert Smith, PhD, senior vice ...

“Liquid biopsies” make headlines for their potential to detect multiple cancers in their earliest stages, but it’s too soon to tell whether the tests are accurate and safe enough for widespread use, ...

The optimal duration of checkpoint inhibitor immunotherapy is unknown. Pivotal clinical trials typically tested these medications for up to two years, but in practice, some patients continue to use ...

Combination regimens taken for a fixed duration can work as well as a continuous course of a single drug for initial treatment of chronic lymphocytic leukemia (CLL), according to research presented at ...

SAN ANTONIO – An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR ...

After three years of follow-up, most patients treated with Breyanzi remained in remission.

As federal and state funding for health programs shrinks, the Knight Cancer Institute at Oregon Health & Science University just hit the jackpot: A $2 billion donation from Nike cofounder Phil Knight, ...

Federally funded clinical trials provide crucial support for essential areas of cancer care that are not well funded by pharmaceutical companies, according to new research presented at the 2025 ASCO ...

The FDA’s approval of tazemetostat, specifically for patients with advanced or metastatic epithelioid sarcoma who are not eligible for curative surgery, is the first approval of an epigenetic drug for ...